Jose M. Cotrina

Jose M. Cotrina

Auto-generated profile, based on publicly available information

Jose M. Cotrina

Instituto Nacional de Enfermedades Neoplasicas 2 , Lima, Peru

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2019 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CCCarlos Castaneda
Carlos Castaneda
MCM. Castillo
M. Castillo
Carlos Antonio Torres-CabalaCarlos Antonio Torres-Cabala
Carlos Antonio Torres-Cabala
LBL. A. Bernabe
L. A. Bernabe
SCSandro Casavilca-Zambrano
Sandro Casavilca-Zambrano
JAJ. Abugattas
J. Abugattas

17 October 2019 in Biomarkers in Medicine
Verified
Journal Article
Closed access
CCCarlos Castaneda
Carlos Castaneda
MCMiluska Castillo
Miluska Castillo
KAKarina Aliaga
Karina Aliaga
LBLuis A Bernabe
Luis A Bernabe
SCSandro Casavilca-Zambrano
Sandro Casavilca-Zambrano
HGHenry Guerra
Henry Guerra
Aim: To correlate levels of tumor-infiltrating lymphocytes (TIL) evaluated using the International Immuno-Oncology Biomarker Working Group methodology, and both density of tumor-infiltrating immune...

1 February 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
OAOscar Acosta
Oscar Acosta
JPJaime Ponce
Jaime Ponce
JCJosé Cotrina
José Cotrina
AAAlfredo Aguilar
Alfredo Aguilar
JBJosé Luis Buleje
José Luis Buleje
Background: Cell‐free DNA (cfDNA) is used in clinical research to identify biomarkers for diagnosis of and follow‐up on cancer. Here, we propose a fast and innovative approach using traditional housekeeping genes as cfDNA targets in a copy number analysis. We focus on the application of highly sensitive technology such as digital PCR (dPCR) to differentiate breast cancer (BC) patients and controls by quantifying regions of PUM1 and RPPH1 (RNase P) in plasma samples.Methods: We conducted a case‐control study with 82 BC patients and 82 healthy women. cfDNA was isolated from plasma using magnetic beads and quantified by spectrophotometry to estimate total cfDNA. Then, both PUM1 and RPPH1 genes were specifically quantified by dPCR. Data analysis was calibrated using a reference genomic DNA in different concentrations.Results: We found RNase P and PUM1 values were correlated in the patient group (intraclass correlation coefficient [ICC] = 0.842), but they did not have any correlation in healthy women (ICC = 0.519). In dPCR quantification, PUM1 showed the capacity to distinguish early‐stage patients and controls with good specificity (98.67%) and sensitivity (100%). Conversely, RNase P had lower cfDNA levels in triple‐negative BC patients than luminal subtypes (p < 0.025 for both), confirming their utility for patient classification.Conclusion: We propose the PUM1 gene as a cfDNA marker for early diagnosis of BC and RNase P as a cfDNA marker related to hormonal status and subtype classification in BC. Further studies with larger sample sizes are warranted.

3 December 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
XHXiaosong Huang
Xiaosong Huang
PLPaul C Lott
Paul C Lott
DHDonglei Hu
Donglei Hu
VZValentina Zavala
Valentina Zavala
ZJZoeb N Jamal
Zoeb N Jamal
LFLaura Fejerman
Laura Fejerman
Background: A substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been identified mostly in individuals of European (EUR) and Asian ancestries, have been combined to construct a polygenic risk score (PRS) to predict breast cancer risk, but the prediction accuracy of existing PRSs in Hispanic/Latinx individuals (H/L) remain relatively low. We assessed the performance of several existing PRS panels with and without addition of H/L-specific variants among self-reported H/L women. Methods: PRS performance was evaluated using multivariable logistic regression and the area under the ROC curve. Results: Both EUR and Asian PRSs performed worse in H/L samples compared with original reports. The best EUR PRS performed better than the best Asian PRS in pooled H/L samples. EUR PRSs had decreased performance with increasing Indigenous American (IA) ancestry, while Asian PRSs had increased performance with increasing IA ancestry. The addition of two H/L SNPs increased performance for all PRSs, most notably in the samples with high IA ancestry, and did not impact the performance of PRSs in individuals with lower IA ancestry. Conclusions: A single PRS that incorporates risk variants relevant to the multiple ancestral components of individuals from Latin America, instead of a set of ancestry-specific panels, could be used in clinical practice. Impact: The results highlight the importance of population-specific discovery and suggest a straightforward approach to integrate ancestry-specific variants into PRSs for clinical application.

1 September 2020 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MGMarco Galvez-Nino
Marco Galvez-Nino
KRKatia Roque
Katia Roque
LBL. Bernabe
L. Bernabe
MGM. Castillo Garcia
M. Castillo Garcia
JSJ. Sanchez
J. Sanchez
CAC. Castaneda Altamirano
C. Castaneda Altamirano

6 February 2025
Verified
Other
Open access
XHXiaosong Huang
Xiaosong Huang
PLPaul C. Lott
Paul C. Lott
DHDonglei Hu
Donglei Hu
VZValentina Zavala
Valentina Zavala
ZJZoeb N. Jamal
Zoeb N. Jamal
LFLaura Fejerman
Laura Fejerman
Supplemental Table S9 shows variants in European or Asian PRS panels with high linkage disequilibrium (LD) with rs851980